Opdivo generated revenues of just under $5 billion last year, compared with Keytruda's $3.8 billion ... Bavencio, and Imfinzi, respectively. But BMS is not giving up the fight and has come ...

Keytruda’s lead in the category and dominant position in NSCLC overall could make it tough to dislodge, although, Opdivo has one ... and AstraZeneca’s Imfinzi (durvalumab) are both being ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begins in 2028.

Opdivo is part of a class of drugs called PD-1 inhibitors, which enhance the immune system's ability to fight cancer by removing its natural brakes. Like other PD-1 drugs such as Merck's Keytruda ...

Data presented at the ASCO Gastrointestinal Cancers Symposium showed the regimen may be a new option, but it comes with more treatment and financial toxicity.

The combination of Opdivo and Yervoy is supported by updated results as a standard of care for MSI-H or dMMR metastatic ...

A chemotherapy-free regimen of neoadjuvant nivolumab (Opdivo) with or without ipilimumab (Yervoy) induced immune activation in a majority of patients with early triple-negative breast cancer (TNBC ...

Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for patients with solid tumors. The Food and Drug Administration (FDA) approval of ...

Dec 27 (Reuters) - (This Dec. 27 story has been corrected to say Opdivo Qvantig has been approved ... drugs such as Merck's (MRK.N), opens new tab Keytruda, it was previously available through ...